Rezdiffra (Resmetirom) Cardiovascular Impact Long-Term

Why Cardiovascular Risk Sits at the Center of MASH Management

MASH is not only a liver disease. Patients with MASH carry a substantially elevated burden of cardiovascular disease (CVD), and CVD, not liver failure, is the leading cause of death in this population. A 2023 systematic review and meta-analysis published in Alimentary Pharmacology and Therapeutics reported that patients with NAFLD/MASH have a 64% higher risk of fatal or non-fatal cardiovascular events compared with the general population (1). That figure underscores why any MASH-specific therapy must be evaluated not only for liver histology but also for cardiometabolic signal.

The Metabolic Overlap Between MASH and Atherosclerosis

MASH and atherosclerotic cardiovascular disease (ASCVD) share overlapping drivers: insulin resistance, atherogenic dyslipidemia, visceral adiposity, and systemic inflammation (2). Hepatic steatosis accelerates the overproduction of very-low-density lipoprotein (VLDL) particles, which in turn raises small dense LDL and lowers HDL, a pattern that predicts coronary events independently of total cholesterol (3).

Where THR-β Selectivity Becomes Relevant

Thyroid hormone receptor exists in two main isoforms: alpha (THR-α, dominant in heart and bone) and beta (THR-β, dominant in liver). Earlier non-selective thyroid hormone analogs raised concerns about tachycardia, bone loss, and muscle wasting because they activated THR-α peripherally. Resmetirom's high selectivity for THR-β over THR-α (roughly 28-fold binding preference) confines the primary pharmacological action to hepatocytes, making cardiac safety a more tractable target (4). The FDA label does include a warning about potential cardiac effects, specifically QTc prolongation at supratherapeutic exposures, and prescribers should review the full Prescribing Information accordingly (5).

MAESTRO-NASH: The Key 52-Week Dataset

MAESTRO-NASH was a Phase 3, randomized, double-blind, placebo-controlled trial enrolling 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F3. The primary co-endpoints were NASH resolution without worsening fibrosis, and fibrosis improvement by at least one stage without worsening NASH activity. Harrison and colleagues published results in The New England Journal of Medicine in February 2024 (4).

Primary Histological Outcomes

NASH resolution (defined as NAS ballooning score of 0, inflammation score of 0 or 1, and no worsening fibrosis) was achieved in 25.9% of patients receiving resmetirom 80 mg and 29.9% receiving 100 mg, compared with 9.7% on placebo (P<0.001 for both comparisons). One-stage fibrosis improvement occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo (P<0.001) (4).

Lipid and Lipoprotein Changes as Cardiovascular Surrogates

The trial prespecified lipid biomarkers as secondary endpoints. At week 52, resmetirom 80 mg reduced LDL-cholesterol by 12.6% and the 100 mg dose reduced it by 16.3%, versus a 0.1% increase in the placebo group. Apolipoprotein B (ApoB), widely regarded as a more accurate ASCVD risk marker than LDL-C, fell by 13.9% (80 mg) and 16.3% (100 mg) relative to placebo (4). ApoB is recommended as the primary lipid target in the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias (6). Triglycerides dropped by 21.6% (80 mg) and 27.7% (100 mg) versus placebo, and lipoprotein(a) fell by approximately 20 to 26% across dose groups, a finding of particular interest given that Lp(a) is a genetically determined, largely treatment-resistant cardiovascular risk factor with no currently approved pharmacotherapy in the United States (4, 7).

The Lp(a) Signal: A Potentially Differentiated Benefit

Lipoprotein(a) reduction deserves separate discussion. Lp(a) circulates as a modified LDL particle with an additional apolipoprotein(a) chain and independently predicts myocardial infarction and aortic stenosis. The American Heart Association and American College of Cardiology 2018 Cholesterol Guideline identifies Lp(a) above 50 mg/dL as a risk-enhancing factor that should push clinicians toward more aggressive statin use (8). An approximately 20 to 26% reduction from a once-daily oral agent is a noteworthy signal, though the clinical event reduction associated with that magnitude of Lp(a) lowering from resmetirom has not yet been demonstrated in a dedicated outcomes trial.

Cardiac Safety Profile: What the Trial Data Show

Heart Rate and Rhythm

Resmetirom's THR-β selectivity was designed to avoid the tachycardia associated with non-selective thyroid mimetics. In MAESTRO-NASH, mean heart rate changes from baseline were small and not clinically meaningful across either dose arm (4). The FDA label notes QTc interval data from a thorough QT study: resmetirom at 1.5 times the maximum therapeutic dose produced a maximum mean QTcF prolongation of 6.3 ms, which is below the 10 ms threshold that typically triggers regulatory concern (5).

Blood Pressure

Thyroid hormone in supraphysiologic doses is known to reduce systemic vascular resistance and lower diastolic blood pressure. Because resmetirom acts primarily on hepatic THR-β, systemic hemodynamic effects were modest in MAESTRO-NASH. Blood pressure was not a prespecified primary or secondary endpoint, and no statistically significant change in mean arterial pressure was reported across dose groups (4).

Major Adverse Cardiovascular Events in MAESTRO-NASH

The 52-week trial duration was not powered to detect differences in cardiovascular events. MACE (major adverse cardiovascular events) were collected as adverse events of special interest. Event rates were low and numerically balanced across groups, consistent with the short observation window and a trial population that, while metabolically at-risk, was not selected for existing ASCVD (4). Long-term event data must come from MAESTRO-NASH-OUTCOMES (9).

Mechanisms by Which Hepatic THR-β Activation Affects Cardiovascular Biology

Lipid Synthesis and Export

THR-β in hepatocytes governs the transcription of genes controlling cholesterol synthesis (HMGCR, PCSK9), fatty acid oxidation, and VLDL assembly. Resmetirom upregulates hepatic LDL receptor expression and reduces PCSK9 secretion, which accelerates LDL clearance from the circulation (10). This dual mechanism, increased LDL receptor density plus lower PCSK9-mediated receptor degradation, mirrors the combined action pathway of statins and PCSK9 inhibitors, though the magnitude is considerably smaller than either class alone. Co-administration with statins or ezetimibe is common in the MASH population given high baseline CVD risk, and no pharmacokinetic interaction has been identified that would preclude combination use (5).

Hepatic Triglyceride Metabolism

Resmetirom activates mitochondrial fatty acid beta-oxidation genes, including CPT1A and ACOX1, reducing intrahepatic triglyceride accumulation (11). Lower hepatic triglyceride content directly curtails VLDL-triglyceride secretion, which in turn reduces the substrate available for the formation of atherogenic remnant particles and small dense LDL. This pathway is distinct from statin or fibrate mechanisms, raising the theoretical possibility of additive lipid benefits when these drugs are combined with resmetirom.

Systemic Inflammation

MASH-associated hepatic inflammation generates a stream of pro-inflammatory cytokines, including IL-6, TNF-alpha, and C-reactive protein precursors, that contribute to endothelial dysfunction and plaque instability (12). In MAESTRO-NASH, resmetirom significantly reduced high-sensitivity CRP (hsCRP) from baseline at week 52, with the 100 mg dose showing a median reduction of approximately 38% versus placebo (4). High-sensitivity CRP is an independent predictor of cardiovascular events as established by the JUPITER trial (N=17,802), which found rosuvastatin 20 mg in patients with hsCRP above 2.0 mg/L reduced the composite cardiovascular endpoint by 44% versus placebo (13).

Long-Term Extrapolation: What the Data Support and Where Gaps Remain

Surrogate Endpoint Translation

The surrogate improvements in LDL-C, ApoB, triglycerides, Lp(a), and hsCRP from MAESTRO-NASH are consistent with the direction of reduced cardiovascular risk. The Cholesterol Treatment Trialists' (CTT) Collaboration analysis (N=170,000 across 26 trials) established that each 1.0 mmol/L (approximately 39 mg/dL) reduction in LDL-C reduces major vascular events by about 22% (14). Based on the CTT relationship, the 13 to 16% LDL-C reduction from resmetirom, starting from a mean baseline LDL-C of roughly 107 mg/dL in MAESTRO-NASH, would translate to an absolute LDL-C drop of roughly 13 to 17 mg/dL, or approximately 0.34 to 0.44 mmol/L. That predicts a modest but directionally favorable cardiovascular effect when combined with background lipid-lowering therapy.

The MAESTRO-NASH-OUTCOMES Trial

The ongoing MAESTRO-NASH-OUTCOMES study is a long-term extension and cardiovascular outcomes trial designed to assess hepatic decompensation, liver-related events, and all-cause mortality over a multi-year period in the original MAESTRO-NASH cohort and an expanded population (9). Primary cardiovascular event data from this study are not yet available. Until those results are published, the cardiovascular benefit of resmetirom should be communicated to patients as a biomarker-level signal, not a proven hard-endpoint effect.

Fibrosis Regression and Cardiovascular Risk

Fibrosis stage is an independent predictor of cardiovascular mortality in MASH, separate from lipid levels. A meta-analysis of individual patient data from 17 NAFLD cohorts (N=17,452) demonstrated that each one-stage increase in liver fibrosis was associated with a significant increase in liver-related mortality and cardiovascular mortality (15). Resmetirom's ability to produce fibrosis regression in roughly 24 to 26% of treated patients at 52 weeks may therefore carry cardiovascular mortality benefit through a hepatic structural mechanism that is independent of the lipid changes.

Practical Prescribing Considerations for Cardiovascular Co-Management

Patient Selection

The FDA indication is MASH with moderate-to-severe fibrosis (F2, F3) confirmed by liver biopsy or by validated non-invasive tests meeting the label criteria (5). The typical patient prescribed resmetirom will already be on a statin, and many will be on antihypertensive therapy. Adding resmetirom in this context layers its LDL-C, ApoB, and Lp(a) effects on top of existing cardiovascular risk management.

Dosing and Titration

Resmetirom is initiated at 80 mg orally once daily with food. The dose may be increased to 100 mg once daily after 4 weeks in patients tolerating the lower dose and with a body weight above 100 kg, per the FDA label (5). No dose adjustment is required for mild-to-moderate renal impairment. The drug is a substrate and inhibitor of several CYP and transporter pathways, so the prescriber should review interactions with statins (particularly rosuvastatin and atorvastatin), which are relevant to statin myopathy risk.

Monitoring Lipids and Liver Function

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance on MASH recommends monitoring liver biochemistry (ALT, AST, bilirubin) at 4, 12, and 24 weeks after initiation and every 6 months thereafter (16). Fasting lipid panel at baseline and at 12 weeks provides confirmation of the expected lipid response and helps track combined benefit with background statin therapy. If LDL-C or ApoB remains above guideline targets despite resmetirom plus statin, the clinician may consider adding ezetimibe or a PCSK9 inhibitor, since no drug-drug interaction precludes combination.

Contraindications with Cardiovascular Relevance

Resmetirom is contraindicated in cirrhosis (Child-Pugh B or C) and in patients taking moderate or strong CYP2C8 inhibitors, which include gemfibrozil, a fibrate sometimes used in the MASH dyslipidemia population. Gemfibrozil co-administration is explicitly listed as contraindicated in the FDA label due to substantially elevated resmetirom exposure (5). Fenofibrate, which does not inhibit CYP2C8 to the same degree, is not subject to the same restriction, though the label advises caution.

Synthesizing the Evidence: A Tiered View of Cardiovascular Benefit

The evidence for resmetirom's cardiovascular effects can be organized into three tiers of confidence.

Tier 1 (High confidence, direct trial data): Statistically significant reductions in LDL-C, ApoB, triglycerides, and Lp(a) at 52 weeks, confirmed in a Phase 3 RCT with 966 participants (4). Cardiac safety signal from the thorough QT study showing QTcF prolongation of 6.3 ms at 1.5x therapeutic dose (5).

Tier 2 (Moderate confidence, surrogate extrapolation): Projected ASCVD event reduction based on the CTT LDL-C relationship and the observed 13 to 16% LDL-C drop. The hsCRP reduction of approximately 38% at 100 mg aligns with anti-inflammatory cardiovascular benefit seen with other agents in JUPITER and CANTOS (13, 17). Fibrosis regression in 24 to 26% of patients may reduce cardiovascular mortality through hepatic structural improvement (15).

Tier 3 (Low confidence, hypothesis-generating): Long-term MACE reduction demonstrated in a dedicated outcomes trial. MAESTRO-NASH-OUTCOMES is ongoing, and results have not yet been published.

The AASLD 2023 Practice Guidance states: "Given the high prevalence of cardiovascular disease in patients with NAFLD/MASH, all patients should undergo cardiovascular risk assessment, and management of cardiovascular risk factors should be a central component of MASH care" (16). Resmetirom addresses this by improving multiple lipid and inflammatory biomarkers simultaneously in a patient population that often has undertreated dyslipidemia alongside liver disease.